Annual Meeting will showcase late-breaking, practice-changing clinical trial results
//
Estimated Read Time:
Cancer research continues to accelerate as researchers around the world report groundbreaking advances in new treatments for all types of cancer. The progress is strongly reflected in the quality and quantity of clinical trials submitted for presentation at the AACR Annual Meeting 2023, according to Timothy A. Yap, MD, PhD, Associate Professor, Department of Investigational Cancer Therapeutics, and Medical Director, Institute for Applied Cancer Science, at the University of Texas MD Anderson Cancer Center.
Yap serves as co-chair of the AACR Annual Meeting Clinical Trials Committee alongside Shivaani Kummar, MD, DeArmond Endowed Chair of Cancer Research, Co-director of the Center for Experimental Therapeutics, and Deputy Director for Clinical & Translational Research, Knight Cancer Institute at Oregon Health & Science University.
Along with the clinical trials presented during the daily plenaries, symposia, and poster sessions, the Annual Meeting program features three clinical trials minisymposia and four in-depth clinical trials plenary sessions that will include paired presentations on the science behind the trials.
“We had a record number of high-quality abstracts submitted for our clinical trials sessions this year,” Yap said. “This has led to an incredible lineup of clinical trials, ranging from exciting first-in-class, first-in-human phase I trials of novel agents to phase III practice-changing trials.”
Cancer drugs currently in or emerging from clinical trials range from novel immunotherapy agents, molecularly targeted therapeutics, vaccines, and rational combinations investigated in different cancers in the neoadjuvant, adjuvant, and advanced metastatic settings.
“We will hear the results from key clinical trials of new agents and new targets that are showing great promise for solid tumors, as well as for hematological malignancies,” Kummar said. “These include rational immunotherapy combinations, as well as novel highly selective and specific molecularly targeted agents against RAS, FGFR, YAP1, PIK3CA, and the DNA damage response pathways.”
Following are a few of the abstract presentations scheduled during the Annual Meeting. Check the online planner for the most up-to-date information on session topics, dates, and times, and sign up for news updates from AACR Annual Meeting News to learn more about this year’s clinical trials presentations.
PHASE III ADULT CLINICAL TRIALS
- CT008: Pembrolizumab in combination with gemcitabine and cisplatin for advanced biliary tract cancer: Phase 3 KEYNOTE-966 study
Abstract will be presented during the clinical trials plenary session Hope for Rare Cancers: Novel Targeted and Immunotherapy Agents, Sunday, April 16, 3:30 – 5:30 p.m. ET, W Hall A2-3, Convention Center
- CT003: IMbrave050: Phase 3 study of adjuvant atezolizumab + bevacizumab versus active surveillance in patients with hepatocellular carcinoma (HCC) at high risk of disease recurrence following resection or ablation
Abstract will be presented during the clinical trials plenary session Harnessing the Immune System in the Clinic, Sunday, April 16, 12:45 – 3:15 p.m. ET, Chapin Theater, Convention Center
- CT005: AEGEAN: A phase 3 trial of neoadjuvant durvalumab + chemotherapy followed by adjuvant durvalumab in patients with resectable NSCLC
Abstract will be presented during the clinical trials plenary session Harnessing the Immune System in the Clinic, Sunday, April 16, 12:45 – 3:15 p.m. ET, Chapin Theater, Convention Center
PHASE II ADULT CLINICAL TRIALS
- CT001: A personalized cancer vaccine, mRNA-4157, combined with pembrolizumab versus pembrolizumab in patients with resected high-risk melanoma: Efficacy and safety results from the randomized, open-label Phase 2 mRNA-4157-P201/Keynote-942 trial
Abstract will be presented during the clinical trials plenary session Harnessing the Immune System in the Clinic, Sunday, April 16, 12:45 – 3:15 p.m. ET, Chapin Theater, Convention Center
FIRST-IN-HUMAN PHASE I TRIALS
- CT006: First-in-class, first-in-human phase 1 trial of VT3989, an inhibitor of yes-associated protein (YAP)/transcriptional enhancer activator domain (TEAD), in patients (pts) with advanced solid tumors enriched for malignant mesothelioma and other tumors with neurofibromatosis 2 (NF2) mutations
Abstract will be presented during the clinical trials plenary session Hope for Rare Cancers: Novel Targeted and Immunotherapy Agents, Sunday, April 16, 3:30 – 5:30 p.m. ET, W Hall A2-3, Convention Center
- CT013: Safety and efficacy from the phase 1/2 first-in-human study of REGN5459, a BCMA×CD3 bispecific antibody with low CD3 affinity, in patients with relapsed/refractory multiple myeloma
Abstract will be presented during the clinical trials plenary session Promising Novel Antitumor Strategies in Early Phase Clinical Trials, Monday, April 17, 10:15 a.m. – 12:15 p.m. ET, W Hall A2-3, Convention Center
PHASE I, II, OR, III CLINICAL TRIALS IN PEDIATRIC CANCER
- CT019: Phase I/II study of the PARP inhibitor olaparib and ATR inhibitor ceralasertib in children with advanced malignancies: Arm N of the AcSé-ESMART trial
Abstract will be presented during the clinical trials plenary session Novel Biomarker-driven Molecularly Targeted Therapy Trials, Tuesday, April 18, 10:15 a.m. – 12:15 p.m. ET, Chapin Theater, Convention Center
